Original language | English |
---|---|
Pages (from-to) | 74-74 |
Number of pages | 1 |
Journal | European Journal of Cancer Supplements |
Volume | 6 |
Issue number | 12 |
DOIs | |
Publication status | Published - Oct 2008 |
Event | 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Geneva, Switzerland Duration: 21 Oct 2008 → 24 Oct 2008 |
Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D
A. Townsend, P. Padrik, P. Mainwaring, T. Price, L. Catley, A. Longenecker, M. A. Palladino, G. K. Lloyd, M. A. Spear, M. Millward
Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review
1
Citation
(Web of Science)